Ann: Close of Rights Issue, page-11

As @ShmoShady would say " but wait there's more!!!!!!!!!!!!!!!". @Codgod, you would buy for the reasons below and you also get free options exercisable with a long expiry date. (around March 2026). If the below doesn't excite you, I'm not sure what would. LMFAO

Rhythm engages world-class specialists in the Colorectal Cancer screening and early diagnosis areas;
 Appointment of the Clinical Advisory Board (CAB) will provide expert guidance and oversight throughout the further development process of the ColoSTAT® test kit; and
 The CAB will support Rhythm to ensure the accuracy, safety, and efficacy of the test, as well as its relevance in the clinical practice and towards better patient experience and care.

24 November 2023
R&D has identified an important biomarker combination that can distinguish between patients with lung cancer and healthy controls, with >85% sensitivity and >90% specificity BOOM!!!!!!!!!!

These encouraging results warrant confirmation in a larger population and justify the continuation and advancement of the project. Therefore, verification of these results would support the case for investment in a new R&D program to develop, validate, clinically evaluate the performance of the biomarkers, and translate these results into a commercially scalable, proprietary blood test to detect lung cancer early when it is most responsive to potentially curative treatments BOOM BOOM!!!

16 February 2024
- Chief Executive Officer (CEO) executive search in final stages, with short-list Board analysis and interviews underway;
- Re-lodgement of R&D tax incentive (RDTI), expected by early March 2024; (bringing significant cash LMAO)
- Further analytical R&D progress in Gastric Cancer biomarker detection has been reported by Nexomics (powered by the Peter MacCallum Cancer Centre), Rhythm’s research partner in this endeavour. Partner works are expected to complete by the end of 3Q’FY24, with Rhythm’s additional analysis and results to be reported before the end of FY24

Announced a number of times
Re-lodgement of COLOSTAT application to TGA to get on the ARTG to import, export and sell from /to Australia. (end of 2024 calendar year from memory)

But that's not all, The acting CEO is going to buy a stack of shares which shows confidence in the company. That's a good thing right? LOL.

What's not to like? If you want to know the truth and learn about RHY, just look at @josiejow37 posts. Very informative.

Oh shit, I did i forget the R&D into Gastric Cancer. Nobody is doing that around the world I think. LOL